La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It has several product candidates in development. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It is developing LJPC-401 for the potential treatment of iron overload. LJPC-30S is its next-generation gentamicin derivative program.The Company has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. As of December 31, 2016, the ATHOS 3 Phase III trial completed enrollment of over 340 patients.

Bank Name La Jolla Pharmaceutical Company
Stock Exchange NASDAQ
Symbol LJPC
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region Amarica
CEO Dr. George F. Tidmarsh
Employees 309
Registered Year 1989